Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
Yehuda Z. Cohen(Rockefeller University), Marina Caskey(Rockefeller University), Chelsey Bennett(Fred Hutch Cancer Center), Irina Shimeliovich(Rockefeller University), Shu Lin(Dartmouth College), Rebeka Levin(Rockefeller University), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Allan C. deCamp(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Georgia D. Tomaras(National Institutes of Health), Allison L. Butler(Rockefeller University), Roshni Patel(Oxford University Hospitals NHS Trust), Nicole L. Yates(Duke University), Bryan T. Mayer(Fred Hutch Cancer Center), Alicia Sato, Joshua A. Weiner(Dartmouth College), Margaret E. Ackerman(Dartmouth College), Cecilia Unson-O’Brien(Rockefeller University), Michael S. Seaman(Beth Israel Deaconess Medical Center), Julio C. C. Lorenzi(Rockefeller University), Katrina G. Millard(Rockefeller University), Lindsey R. Baden(Brigham and Women's Hospital), Maggi Witmer-Pack(Rockefeller University), Anna Chung-Kwan Tse(Beth Israel Deaconess Medical Center), Kelly E. Seaton(International Vaccine Institute), Jill Horowitz(Rockefeller University), Michel C. Nussenzweig(Howard Hughes Medical Institute)
Cited by 92
Related Papers
Evolution of antibody immunity to SARS-CoV-2
|Nature|2021|1.8k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981